ArticleHeliyon2023
Formulating co-loaded nanoliposomes with gallic acid and quercetin for enhanced cancer therapy.
Article in Heliyon, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it, 38 citations in OpenAlex.
- A Systematic Review: Quercetin-Secondary Metabolite of the Flavonol Class, with Multiple Health Benefits and Low Bioavailability.International journal of molecular sciences · 2024Pooled it
- Development and In Vitro Evaluation of Atorvastatin and Rutin Co-Loaded Nanoliposomes for Enhanced Anti-Inflammatory and Cytotoxic Efficacy.International journal of molecular sciences · 2026Article
- Liposomal drug delivery for lung cancer therapy: progress, challenges, and future perspectives.Molecular cancer · 2026Review
- Development and evaluation of multifunctional niosomal cream encapsulating tretinoin and integrated with hyaluronic acid and ceramides.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- β-Cyclodextrin nanosponges loaded with gallic acid: A promising system for anthocyanins preservation in grape juice.Food chemistry: X · 2026Article
- Phenolic Compounds: From Traditional Uses to Innovative Applications and Everything in Between.Molecular nutrition & food research · 2026Review
- Article
- Harnessing liposomal delivery to boost polyphenols' potential in chronic wound therapy.Frontiers in drug delivery · 2026Article
- A phytotherapeutic approach to hinder the resistance against clindamycin by MRSA:Future science OA · 2025Article
- Natural product-based nanotechnological formulations for colorectal cancer treatment.Naunyn-Schmiedeberg's archives of pharmacology · 2025Review
- Codelivery of Raloxifene and Rutin as PEGylated Nanoliposomes: Formulation, Characterization, and Prophylactic Activity Against Breast Cancer.Advanced pharmaceutical bulletin · 2025Article
- Impact of hydroxyapatite nanoparticles on the cellular processes of stem cells derived from dental tissue sources.Cell and tissue research · 2025Article
- Harnessing Polyphenols and Novel Delivery Strategies for Effective Treatment of Breast Cancer.Recent advances in drug delivery and formulation · 2025Review
- Green synthesizedFuture science OA · 2024Article
- Nanoquercetin based nanoformulations for triple negative breast cancer therapy and its role in overcoming drug resistance.Discover oncology · 2024Review
- Recent Advancements in Gallic Acid-Based Drug Delivery: Applications, Clinical Trials, and Future Directions.Pharmaceutics · 2024Review
- Preparation, characterization andTherapeutic delivery · 2024Article
- Gallic acid: a dietary metabolite's therapeutic potential in the management of atherosclerotic cardiovascular disease.Frontiers in pharmacology · 2024Review
- Oleuropein impact on colorectal cancer.Future science OA · 2024Review
- Quercetin in Oncology: A Phytochemical with Immense Therapeutic Potential.Current drug targets · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer is considered one of the top global causes of death. Natural products have been used in oncology medicine either in crude form or by utilizing isolated secondary metabolites. Biologically active phytomolecules such as gallic acid and quercetin have confirmed antioxidant, anti-bacterial, and neoplastic properties. There is an agreement that microorganisms could mediate oncogenesis or alter the immune system. This research project aims to develop a novel formulation of co-loaded gallic acid and quercetin into nanoliposomes and investigate the efficacy of the free and combined agents against multiple cancerous cell lines and bacterial strains. Thin-film hydration technique was adopted to synthesize the nanocarriers. Particle characteristics were measured using a Zetasizer. The morphology of nanoliposomes was examined by scanning electron microscopy, Encapsulation efficiency and drug loading were evaluated using High-Performance Liquid Chromatography. Cytotoxicity was determined against Breast Cancer Cells MCF-7, Human Carcinoma Cells HT-29, and A549 Lung Cancer Cells. The antibacterial activities were evaluated against
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.